To evaluate whether lowering Atp1a2 using ASOs might alter ALS disease course and outcome in SOD1*G93A mice, mice were treated with a single ICV bolus of either ctrl ASO (50 and 25μg), ASO1 (50μg), or ASO3 (25μg) at 5–8 weeks of age, prior to onset of phenotype of neurodegeneration (Fig 4A). This evidence concerns the gene ATP1A2 and amyotrophic lateral sclerosis.